Recurrence/Regrowth in Grade I Meningioma: How to Predict?

• Published in: Frontiers in oncology Vol. 10; p. 1144
• Main Authors: Carvalho, Gervásio Teles Cardoso de, Silva-Martins, Warley Carvalho da, Magalhães, Kênia Cristina Soares Fonseca de, Nunes, Cristiana Buzelin, Soares, Aleida Nazareth, Tafuri, Luciene Simões de Assis, Simões, Renata Toscano
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 04.08.2020
• Subjects: HLA-E; HLA-G; hormonal receptors; immunomarkers; inflammatory biomarkers; MIB-1; Oncology
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2020.01144

The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth ( p = 0.486), but was significantly correlated with peritumoral edema ( p = 0.031) and intratumoral calcifications ( p = 0.018). Recurrent meningiomas were observed in 14.6% of cases. Immunostaining for each marker was: HLA-G 100%; HLA-E 95.6%; PR 62%; ER 2.1%; AR 6.5%; p53 92.6%; COX-2 100%; HER2 0%; Ki67, mean 2.61 ± 2.29%, median 2.1%. Primary and recurrent meningiomas showed no significant relation with HLA-E and hormone receptors ( p > 0.05), except for Ki67, where a higher median was observed in recurrent tumors than in primary ( p = 0.014). The larger the tumor, the more severe the peritumoral edema, and the greater the presence of calcifications. Ki67 appears to be a good biomarker of recurrence/regrowth in grade I meningiomas.